HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn’s disease patients

Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study

(2021) Andreas Blesl et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Predictors of drug survival: A cohort study comparing anti‐tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register

(2021) Isabella Visuri et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update

(2020) Marianne Vulliemoz et al.   DIGESTION

Real‐World Infliximab Pharmacokinetic Study Informs an Electronic Health Record‐Embedded Dashboard to Guide Precision Dosing in Children with Crohn’s Disease

(2020) Ye Xiong et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

LncRNA SNHG7 alleviates IL-1β-induced osteoarthritis by inhibiting miR-214-5p-mediated PPARGC1B signaling pathways

(2020) Junkui Xu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease

(2019) Aze Wilson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Inhibition of miR-378a-3p by Inflammation Enhances IL-33 Levels: A Novel Mechanism of Alarmin Modulation in Ulcerative Colitis

(2019) Karen Dubois-Camacho et al.   Frontiers in Immunology

HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease

(2019) Aleksejs Sazonovs et al.   GASTROENTEROLOGY

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience

(2018) Gary R Lichtenstein et al.   INFLAMMATORY BOWEL DISEASES

Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy—a Post-hoc analysis

(2018) Jean Frederic Colombel et al.   Clinical Gastroenterology and Hepatology

PPARGC1B gene is associated with Kashin-Beck disease in Han Chinese

(2016) Yan Wen et al.   FUNCTIONAL & INTEGRATIVE GENOMICS

Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis

(2016) Young Ho Lee et al.   RHEUMATOLOGY INTERNATIONAL

Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases

(2015) K. Papamichael et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Infliximab-Related Infusion Reactions: Systematic Review

(2015) Lev Lichtenstein et al.   Journal of Crohns & Colitis

Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals

(2015) Yosuke Kawai et al.   JOURNAL OF HUMAN GENETICS

MAGMA: Generalized Gene-Set Analysis of GWAS Data

(2015) Christiaan A. de Leeuw et al.   PLoS Computational Biology

Second-generation PLINK: rising to the challenge of larger and richer datasets

(2015) Christopher C Chang et al.   GigaScience

Inflammatory cytokines promote growth of intestinal smooth muscle cells by induced expression of PDGF-Rβ

(2014) Dileep G. Nair et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia

(2014) Suk-Kyun Yang et al.   NATURE GENETICS

PGC-1β promotes enterocyte lifespan and tumorigenesis in the intestine

(2014) Elena Bellafante et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CrossMap: a versatile tool for coordinate conversion between genome assemblies

(2013) Hao Zhao et al.   BIOINFORMATICS

FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity

(2013) Rintaro Moroi et al.   IMMUNOGENETICS

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies

(2010) Fernando Magro et al.   BIODRUGS

LocusZoom: regional visualization of genome-wide association scan results

(2010) R. J. Pruim et al.   BIOINFORMATICS

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease

(2009) Malgorzata Krzystek-Korpacka et al.   CLINICAL BIOCHEMISTRY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS